Founded in 2008, the BioNTech Group has become one of the fastest-growing biotechnology companies in Europe. The development of fundamentally novel, cutting-edge biopharmaceuticals for treatment of many diseases with high medical need drives our success.
We are committed to serving patient needs by making medicine truly personal. Our vision is to offer precisely targeted, highly effective, and well-tolerated therapies – innovative medicines as unique as you!
|MERIT||RNA-based cancer vaccine targeting two tumor-associated antigens (Malignant Melanoma)|
|IVAC MUTANOME||Two RNA-based cancer vaccines targeting two tumor-associated antigens as well as tumor-specific mutations (Malignant Melanoma)|
|GAPVAC||Actively personalized vaccination concept in newly diagnosed glioblastoma patients (Glioblastoma)|
|TNBC-MERIT||RNA-lipoplex cancer vaccines targeting tumor-associated antigens (IVAC®WAREHOUSE) as well as tumor-specific mutations (IVAC® MUTANOME) (Triple negative breast cancer)|
|Lipo-MERIT||RNA-lipoplex cancer vaccine targeting four tumor-associated antigens (Malignant Melanoma)|
2015 October 8, Workshop: 2 Update prädiktive molekularpathologische Diagnostik, Frankfurt, Germany
2015 November 2-4, BIO Europe, Munich, Germany
2015 November 4-8, SITC, National Harbor, USA
2015 November 11-12, International mRNA Health Conference, Berlin, Germany
2015 November 16-19, Medica, Düsseldorf, Germany
2015 November 18-20, Therapeutic Area Partnerships, Boston, USA
Interested in meeting with us?
Please contact our Business Development Department
Newspapers and Magazines
TV – Reports
SWR Rheinland-Pfalz – Forscher entwickeln Krebsimpfstoff